Chronic Subdural Hematoma - Reduction of Recurrence by Treatment With Angiotensin Converting Enzyme Inhibitors
NCT ID: NCT00915928
Last Updated: 2020-08-19
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
47 participants
INTERVENTIONAL
2009-07-31
2012-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tranexamic Acid in Chronic Subdural Hematomas
NCT02568124
Study of Antithrombotic Treatment After IntraCerebral Haemorrhage
NCT03186729
High Dose Hyperoncotic Serum Albumin for the Treatment of the Acute Phase of Severe Head Injury
NCT00152685
Tranexamic Acid in the Treatment of Residual Chronic Subdural Hematoma -2
NCT04898712
Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage.
NCT05131295
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ACE inhibitor
patients randomized to this arm will be treated with ACE inhibitors after surgery
Perindopril
2,5 mg daily for 3 months
Placebo
patients randomized to this arm will be treated with placebo after surgery
Placebo
Placebo dayli for 3 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Perindopril
2,5 mg daily for 3 months
Placebo
Placebo dayli for 3 months
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age \> 18 year
Exclusion Criteria
2. Kidney artery stenosis
3. Stenosis of the aorta
4. Severely decreased kidney function
5. Allergy or intolerance/contraindications toward ACE inhibitors
6. Already in ACE inhibitor treatment
7. Coagulopathies
8. Malignant disorders
9. Fertile women
10. Other neurological disorders
11. Treatment with pharmaceuticals contraindicating treatment with ACE inhibitors
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alice Brenaa Foundation
OTHER
The Hede Nielsen Family Foundation
OTHER
Overlægerådets legatudvalg
UNKNOWN
University of Southern Denmark
OTHER
Odense University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Frantz Rom Poulsen
MD PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Frantz R Poulsen, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Neurosurgery, Odense University Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Eudra CT nummer 2009-010058-37
Identifier Type: -
Identifier Source: secondary_id
Chronic Subdural Hematoma
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.